A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis

被引：0
作者：
Rao, Shiavax J. [1 ]
Kumar, Kaushik [1 ]
Saleh, Nahar [1 ]
机构：
[1] MedStar Union Mem Hosp, Internal Med, Baltimore, MD 21218 USA
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2022年 / 14卷 / 10期
关键词：
high anion gap metabolic acidosis; sglt-2; inhibitor; euglycemic dka; diabetic keto acidosis; sodium-glucose cotransporter-2 inhibitors;
D O I：
10.7759/cureus.30106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA.
引用
收藏
页数：4
相关论文
共 10 条
  • [1] Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
    Abdul-Ghani, Muhammad A.
    Norton, Luke
    DeFronzo, Ralph A.
    [J]. ENDOCRINE REVIEWS, 2011, 32 (04) : 515 - 531
  • [2] SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
    Ata, Fateen
    Yousaf, Zohaib
    Khan, Adeel Ahmad
    Razok, Almurtada
    Akram, Jaweria
    Ali, Elrazi Awadelkarim Hamid
    Abdalhadi, Ahmed
    Ibrahim, Diaeldin Abdelgalil
    Al Mohanadi, Dabia Hamad S. H.
    Danjuma, Mohammed, I
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Heidenreich, Paul A.
    Bozkurt, Biykem
    Aguilar, David
    Allen, Larry A.
    Byun, Joni J.
    Colvin, Monica M.
    Deswal, Anita
    Drazner, Mark H.
    Dunlay, Shannon M.
    Evers, Linda R.
    Fang, James C.
    Fedson, Savitri E.
    Fonarow, Gregg C.
    Hayek, Salim S.
    Hernandez, Adrian F.
    Khazanie, Prateeti
    Kittleson, Michelle M.
    Lee, Christopher S.
    Link, Mark S.
    Milano, Carmelo A.
    Nnacheta, Lorraine C.
    Sandhu, Alexander T.
    Stevenson, Lynne Warner
    Vardeny, Orly
    Vest, Amanda R.
    Yancy, Clyde W.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (17) : E253 - E421
  • [4] Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management
    Long, Brit
    Lentz, Skyler
    Koyfman, Alex
    Gottlieb, Michael
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2021, 44 : 157 - 160
  • [5] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS
    NARANJO, CA
    BUSTO, U
    SELLERS, EM
    SANDOR, P
    RUIZ, I
    ROBERTS, EA
    JANECEK, E
    DOMECQ, C
    GREENBLATT, DJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) : 239 - 245
  • [6] Plewa MC, 2022, EUGLYCEMIC DIABETIC
  • [7] Rawla P, 2017, ENDOCRINOL DIAB META, DOI 10.1530/EDM-17-0081
  • [8] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Edwards, Jonathan L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11) : 1093 - 1093
  • [9] Sinha Nupur, 2014, Case Rep Crit Care, V2014, P906283, DOI 10.1155/2014/906283
  • [10] The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
    Xu, Bo
    Li, Shaoqian
    Kang, Bo
    Zhou, Jiecan
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
1